RESCAP is under clinical development by Alloksys Life Sciences and currently in Phase III for Acute Renal Failure (ARF) (Acute Kidney Injury). According to GlobalData, Phase III drugs for Acute Renal Failure (ARF) (Acute Kidney Injury) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the RESCAP LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RESCAP overview
Alloksys Life Sciences overview
Alloksys Life Sciences (Alloksys) operates as a drug development company that develops therapies for patients clinicians and researchers. The company manufactures therapeutic proteins for the treatment of chronic and acute inflammatory diseases. Its therapeutic platform RESCAP is used for preventing adverse downstream complications such as systemic inflammations, issue damage and organ failure during and after major surgery. RESCAP also protects maintains and restores physiological barriers, such as Blood Brain Barrier(BBB), Lung Alveolar Barrier(LAB), Kidney Glomerulus Barrier (KGB) Lung Alveolar Barrier(LAB), Gut Barrier (GB) and Placental Barrier (PB). Alloksys is headquartered in Wageningen, the Netherlands.
For a complete picture of RESCAP’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
